NDA 021752 · Gilead
Truvada
Emtricitabine, Tenofovir Disoproxil Fumarate · Oral · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Accelerated approvalPriority reviewLast checked: Nov 20, 2026Latest source record: Apr 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Aug 2, 2004
Approved uses
6
Original approval plus efficacy supplements
Registered trials
684
198 Phase 3, 28 recruiting
FAERS reports
45,437
38,317 serious, 1,835 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B and RISK OF DRUG RESISTANCE WITH USE OF TRUVADA FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED EARLY HIV-1 INFECTION Severe acute exacerbations of hepatitis B (HBV) have been reported in HBV-infected individuals who have discontinued TRUVADA. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in individuals who are infected with HBV and discontinue TRUVADA. If appropriate, anti-hepatitis B therapy may be warranted [see Warnings and Precautions (5.1) ] . TRUVADA used for HIV-1 PrEP must only be prescribed to individuals confirmed to be HIV-negative immediately prior to initiating and at least every 3 months during use. Drug-resistant HIV-1 variants have been identified with use of TRUVADA for HIV-1 PrEP following undetected acute HIV-1 infection. Do not...
What it is approved for
From the label in effect Jul 16, 2025.
HIV-1 Treatment ( 1.1 ) TRUVADA is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated: in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg. HIV-1 PrEP ( 1.2 ): TRUVADA is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP. 1.1 Treatment of HIV-1 Infection TRUVADA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg [see Clinical Studies (14) ] . 1.2 HIV-1 Pre-Exposure Prophylaxis (PrEP) TRUVADA is indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating TRUVADA for HIV-1 PrEP [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] .
Mechanism: TRUVADA is a fixed-dose combination of antiviral drugs FTC and TDF [see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines · Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 15, 2018 Supplement 55 · Efficacy · priority review LetterLabel
- Mar 10, 2016 Supplement 47 · Efficacy LabelLetter
- Jul 16, 2012 Supplement 30 · Efficacy · priority review Summary ReviewLetterLabel
- May 16, 2008 Supplement 16 · Efficacy Letter
- Mar 8, 2006 Supplement 5 · Efficacy LabelLetter
- Aug 2, 2004 Original approval · Type 4 - New Combination · priority review Accelerated approvalPediatric Medical ReviewPediatric Clinical Pharmacology ReviewLetter
4 products under this application
- TRUVADA · EMTRICITABINE 167MG; TENOFOVIR DISOPROXIL FUMARATE 250MG · TABLET, ORAL · Prescription · TE AB
- TRUVADA · EMTRICITABINE 100MG; TENOFOVIR DISOPROXIL FUMARATE 150MG · TABLET, ORAL · Prescription · TE AB
- TRUVADA · EMTRICITABINE 133MG; TENOFOVIR DISOPROXIL FUMARATE 200MG · TABLET, ORAL · Prescription · TE AB
- TRUVADA · EMTRICITABINE 200MG; TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Emtricitabine" as an intervention, any sponsor and status, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- Expanded PrEP Implementation in Communities in NSWPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT02870790 · 9,733 participants · Start Mar 2016 · Primary completion Mar 2019
Drug: TDF/FTC · For: HIV; STI
Sites: Canberra, Australia; Albury, Australia; Alexandria, Australia · 31 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
- Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV InfectionPivotal-lookingActive, not recruiting
Gilead SciencesGilead Sciences (GILD)
NCT04994509 · 5,368 participants · Start Aug 30, 2021 · Primary completion May 27, 2024
Drug: Oral Lenacapavir (LEN); Subcutaneous (SC) Lenacapavir (LEN) and 6 more · For: Pre-Exposure Prophylaxis of HIV Infection
Sites: Brits, South Africa; Cape Town, South Africa; Durban, South Africa · 28 sites in all
- Safety and Effectiveness of TFV 1% Gel, TDF Tablets, and FTC/TDF Tablets in Preventing HIV in WomenPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00705679 · 5,029 participants · Start Aug 2009 · Primary completion Aug 2012
Drug: Emtricitabine/tenofovir disoproxil fumarate; Emtricitabine/tenofovir disoproxil fumarate placebo and 4 more · For: HIV Infections
Sites: Johannesburg, South Africa; Asherville, South Africa; Chatsworth, South Africa · 15 sites in all
- The Partners Scale-Up ProjectCompleted
University of WashingtonAcademic, hospital or other
NCT03052010 · 4,898 participants · Start Feb 6, 2017 · Primary completion Dec 15, 2020
Drug: PrEP; ART · For: HIV-1-infection
Sites: Kisumu, Kenya; Thika, Kenya
- Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant CouplesPivotal-lookingCompleted
University of WashingtonAcademic, hospital or other
NCT00557245 · 4,758 participants · Start May 2008 · Primary completion Oct 2013
Drug: Tenofovir Disoproxil Fumarate (TDF); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and 1 more · For: HIV-1 Infections; HIV Infections
Sites: Eldoret, Kenya; Kisumu, Kenya; Nairobi, Kenya · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- bone density decreased16,618
- chronic kidney disease10,394
- osteonecrosis9,164
- bone loss9,115
- renal failure9,049
- multiple fractures8,191
- tooth loss8,163
- renal injury8,010
- osteoporosis7,326
- skeletal injury7,181
- pain6,586
- emotional distress6,351
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 150 |
| 2006 | 395 |
| 2007 | 518 |
| 2008 | 906 |
| 2009 | 1,204 |
| 2010 | 1,078 |
| 2011 | 986 |
| 2012 | 1,141 |
| 2013 | 1,243 |
| 2014 | 1,476 |
| 2015 | 1,661 |
| 2016 | 1,419 |
| 2017 | 1,295 |
| 2018 | 1,667 |
| 2019 | 2,994 |
| 2020 | 14,655 |
| 2021 | 4,707 |
| 2022 | 2,977 |
| 2023 | 1,589 |
| 2024 | 1,567 |
| 2025 | 1,346 |
| 2026 | 462 |
Recalls
1 FDA enforcement reports for this application.
Sep 30, 2014 · Class III · Terminated
Presence of Foreign Substance: Truvada was found to contain small red silicone rubber particulates.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Truvada (Emtricitabine/Tenofovir (Tdf))
2024 spending
$3.9M
Beneficiaries
578
1,932 claims
Per beneficiary
$6,728
$57.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $164,325,556 |
| 2021 | $36,297,990 |
| 2022 | $9,076,232 |
| 2023 | $5,529,868 |
| 2024 | $3,888,802 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.
Bekker LG, Das M, Abdool Karim Q, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.
O Murchu E, Marshall L, Teljeur C, et al. · BMJ Open 2022 · Meta-Analysis, Systematic Review
- Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W, Zhao S, Wu Y, et al. · JMIR Public Health Surveill 2023 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, et al. · Lancet HIV 2023 · Randomized Controlled Trial, Multicenter Study
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, Molina JM, Thompson MA, et al. · Lancet 2020 · Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis.
Funk AL, Lu Y, Yoshida K, et al. · Lancet Infect Dis 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Gilead Sciences
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.